These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15451944)

  • 21. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen.
    Mohn A; Strang S; Wernicke-Panten K; Lang AM; Edge JA; Dunger DB
    Diabetes Care; 2000 Apr; 23(4):557-9. PubMed ID: 10857953
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia-prone people with Type 1 diabetes.
    Kristensen PL; Tarnow L; Bay C; Nørgaard K; Jensen T; Parving HH; Perrild H; Beck-Nielsen H; Christiansen JS; Thorsteinsson B; Pedersen-Bjergaard U
    Diabet Med; 2017 May; 34(5):625-631. PubMed ID: 28099755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of subcutaneous insulin detemir on glucose flux and lipolysis during hyperglycaemia in people with type 1 diabetes.
    Herring RA; Shojaee-Moradie F; Umpleby AM; Jones R; Jackson N; Russell-Jones DL
    Diabetes Obes Metab; 2015 May; 17(5):459-67. PubMed ID: 25580665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The contribution of intermediate-acting insulin preparations to daytime insulin treatment.
    Robert JJ; Chevenne D; Debray M
    Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Perry CM
    Drugs; 2004; 64(22):2577-95. PubMed ID: 15516157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
    Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
    Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
    J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
    Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial.
    Agesen RM; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Christiansen JS; Jensen T; Hougaard P; Parving HH; Thorsteinsson B; Tarnow L; Pedersen-Bjergaard U
    Diabetes Metab; 2016 Sep; 42(4):249-55. PubMed ID: 27068361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes.
    Herrera KM; Rosenn BM; Foroutan J; Bimson BE; Al Ibraheemi Z; Moshier EL; Brustman LE
    Am J Obstet Gynecol; 2015 Sep; 213(3):426.e1-7. PubMed ID: 26070699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.
    Hollander PA; Blonde L; Rowe R; Mehta AE; Milburn JL; Hershon KS; Chiasson JL; Levin SR
    Diabetes Care; 2004 Oct; 27(10):2356-62. PubMed ID: 15451900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients.
    Rave K; Heinemann L; Puhl L; Gudat U; Woodworth JR; Weyer C; Heise T
    Diabetes Care; 1999 May; 22(5):865-6. PubMed ID: 10332707
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-acting insulin analogs versus human insulins.
    Garg SK; Naik RG
    Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
    [No Abstract]   [Full Text] [Related]  

  • 38. Not all long-acting insulins are the same.
    Harmel AL; Somma L
    Diabetes Care; 2002 Sep; 25(9):1666-7. PubMed ID: 12196454
    [No Abstract]   [Full Text] [Related]  

  • 39. [Insulin glargine improves fasting blood glucose levels in prepubertal children with unsatisfactorily controlled type 1 diabetes].
    Mianowska B; Szadkowska A; Czerniawska E; Pietrzak I; Bodalski J
    Pediatr Endocrinol Diabetes Metab; 2007; 13(4):189-93. PubMed ID: 18042313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.
    Danne T; Lüpke K; Walte K; Von Schuetz W; Gall MA
    Diabetes Care; 2003 Nov; 26(11):3087-92. PubMed ID: 14578244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.